Study: Eli Lilly and Company N1T-MC-MALO “SYNERGY-OUTCOMES”

Written By Patrick Smith

Are you living with metabolic fatty liver disease (also called MASLD)? 

If so, you may be eligible to participate in a clinical research study evaluating the GLP-1 medicines retatrutide and tirzepatide (Zepbound®) for the prevention of long-term complications of metabolic liver disease. 

ABOUT THE STUDY 

This is a Phase 3 study evaluating how retatrutide and tirzepatide (Zepbound) may slow the progression of high-risk metabolic fatty liver disease (MASLD) and help prevent serious liver complications. 

WHO MAY QUALIFY? 

You may be eligible to participate if you meet all the following: 

  • Age 18 years or older 

  • Body mass index (BMI) of 25 or higher (classified as overweight or obesity) 

  • Do not drink more than an average of 3 alcoholic drinks per day (for men) or 2 per day (for women) 

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) within the past 6 months 

  • Have not used any other weight loss medication within the past 3 months 

  • Have never had surgery for treatment of obesity 

  • If diagnosed with type 2 diabetes, have an HbA1c of less than 10% 

INTERESTED IN LEARNING MORE? 

Click below to complete a short questionnaire to see if you may be eligible.
(insert JotForm link - https://www.jotform.com/)

Patrick Smith
Next

This is a placeholder and I’ll delete it.